Santen Pharmaceutical Co., Ltd.
4536.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥540,986 | ¥562,288 | ¥484,054 | ¥557,970 |
| - Cash | ¥63,560 | ¥84,578 | ¥92,997 | ¥77,851 |
| + Debt | ¥35,625 | ¥35,200 | ¥34,229 | ¥31,580 |
| Enterprise Value | ¥513,051 | ¥512,910 | ¥425,286 | ¥511,699 |
| Revenue | ¥69,142 | ¥68,737 | ¥77,231 | ¥76,369 |
| % Growth | 0.6% | -11% | 1.1% | – |
| Gross Profit | ¥37,812 | ¥37,118 | ¥43,722 | ¥42,234 |
| % Margin | 54.7% | 54% | 56.6% | 55.3% |
| EBITDA | ¥15,290 | ¥12,070 | ¥18,656 | ¥15,830 |
| % Margin | 22.1% | 17.6% | 24.2% | 20.7% |
| Net Income | ¥8,062 | ¥5,878 | ¥8,782 | ¥8,693 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS Diluted | 23.7 | 17.28 | 25.69 | 25.23 |
| % Growth | 37.2% | -32.7% | 1.8% | – |
| Operating Cash Flow | ¥5,853 | ¥7,720 | ¥18,890 | ¥13,730 |
| Capital Expenditures | -¥1,532 | -¥1,856 | -¥927 | -¥3,056 |
| Free Cash Flow | ¥4,321 | ¥5,864 | ¥17,963 | ¥10,674 |